A New Steroidal Saponin from Dioscorea cayenensis

Marc SAUTOUR,^{*a*} Anne-Claire MITAINE-OFFER,^{*a*} Tomofumi MIYAMOTO,^{*b*} Alain DONGMO,^{*c*} and Marie-Aleth LACAILLE-DUBOIS^{*,*a*}

^a Laboratoire de Pharmacognosie, Unité UMIB, EA 3660, Faculté de Pharmacie, Université de Bourgogne; 7, Bd. Jeanne d'Arc, BP 87900, 21079 Dijon Cedex, France: ^b Graduate School of Pharmaceutical Sciences, Kyushu University; Fukuoka 812–8582, Japan: and ^c Laboratoire de Biologie des Organismes Animaux, Faculté des Sciences, Université de Douala; 24157, Cameroun. Received April 19, 2004; accepted July 15, 2004

The new $26-O-\beta$ -D-glucopyranosyl- 3β , 26-dihydroxy-20, 22-seco-25(R)-furost-5-en-20, 22-dione-3- $O-\alpha$ -L-rhamnopyranosyl- $(1\rightarrow 4)-\alpha$ -L-rhamnopyranosyl- $(1\rightarrow 4)-[\alpha$ -L-rhamnopyranosyl- $(1\rightarrow 2)]-\beta$ -D-glucopyranoside (1), along with the known methyl protodioscin (2), asperoside (3) and prosapogenin A of dioscin (4) were isolated from the rhizomes of *Dioscorea cayenensis* LAM.-HOLL (Dioscoreaceae). Their structures were established mainly on the basis of 600 MHz 2D-NMR spectral data. 4 exhibited antifungal activity against the human pathogenic yeasts *Candida albicans*, *C. glabrata* and *C. tropicalis* (MICs of 20.8, 6.25, 25 μ g/ml, respectively), whereas saponins 1—3 were inactive.

Key words Dioscorea cayenensis; Dioscoreaceae; steroidal saponin; antifungal activity; 2D-NMR

Our previous phytochemical studies on the methanolic extract of the rhizome of *Dioscorea cayenensis* LAM.-HOLL led to the isolation of a new furostanol saponin.¹⁾ Further detailed investigation of the same extract has resulted in the isolation of a new furostanol glycoside (1) together with three known spirostanol saponins 2—4. Their structures were elucidated mainly by 1D and 2D NMR experiments (COSY, TOCSY, NOESY, HSQC and HMBC), and by HR-ESI-MS and FAB-MS. In addition, the antifungal activity of these compounds against three human pathogenic species of *Candida* is presented.

The *n*-BuOH-soluble fraction of the MeOH- H_2O (7:3) extract of the rhizome of D. cayenensis was subjected to repeated CC over silica gel to yield compounds 1-4. Compound 1, an amorphous powder, showed IR absorptions at 3371 (OH), 2929 (CH), 1736 (CO), 1680 and 1035 cm⁻¹. The high-resolution ESI mass spectrometry (HR-ESI-MS) (positive-ion mode) of 1 exhibited a pseudomolecular ion peak at m/z 1231.5697 [M+Na]⁺ (Calcd 1231.5724), consistent with a molecular formula of C₅₇H₉₂O₂₇Na. Its negativeion FAB-MS showed a guasimolecular ion peak at m/z 1207 $[M-H]^{-}$, indicating a molecular weight of 1208. Acid hydrolysis of 1 yielded glucose, rhamnose (TLC) and an aglycone which was identified as a furostanol-type steroid by comparison of the NMR data of 1 (Table 1) with those of known spirostane-type steroids.¹⁻³⁾ The comparison of NMR data of 1 with literature data allowed the identification of the aglycone as the previously reported $(3\beta, 25R)$ -20,22-seco-25-furost-5-en-20,22-dione-3,26-diol (aglycone of dioscoreside D),^{2,3)} and the five sugar residues as two β -glucopyranosyl (Glc) and three α -rhamnopyranosyl (Rha) moieties. The absolute configurations of glucose and rhamnose were determined to be D and L, respectively, by GC analysis of chiral derivatives of the sugars in the acid hydrolysate (see experimental section). The ¹H- and ¹³C-NMR data of **1** (Tables 1, 2) obtained from its 2D NMR spectra were almost superimposable with those of dioscoreside D,3) except for the presence of an additional terminal α -L-rhamnopyranosyl moiety. The sequence of the four sugars at the C-3 position was indicated by long-range coupling $({}^{3}J)$ in the HMBC spectrum between Rha H-1 (δ =6.10) and Glc I C-2 (δ =78.0), Rha II H-1 (δ =5.58) and Glc I C-4 (δ =77.9) and Rha III H-1 (δ =6.03) and Rha II C-4 (δ =79.8). The linkage of Rha III at the 4-position of Rha II was confirmed by the NOESY correlation observed between the anomeric proton of Rha III at δ =6.03 (s) and the H-4 of Rha II at δ =4.26. The linkage of the fifth remaining sugar at the C-26 position was indicated by long-range coupling (³J) in the HMBC spectrum between Glc II H-1 (δ =4.75) and C-26 (δ =75.6) of the aglycone. On

Table 1. ¹H- and ¹³C-NMR Data^{*a*}) of the Aglycone Part of 1, δ in ppm (*J* in Hz)

	$\delta_{ m C}$	DEPT ^{b)}	$\delta_{\mathrm{H}}^{}^{c,d)}}$
1	37.0	CH ₂	0.90, 1.66
2	31.2	CH_2	nd
3	77.9	CH	3.84
4	38.3	CH ₂	2.60, 2.70
5	140.0	С	
6	121.5	CH	5.30 br s
7	31.6	CH ₂	1.80
8	31.2	CH	1.94
9	49.8	CH	0.80
10	36.4	С	
11	20.6	CH_2	1.30, 1.34
12	39.2	CH_2	1.02, 1.64
13	40.4	С	
14	56.2	CH	0.95
15	31.9	CH ₂	1.40
16	72.3	CH	5.04
17	66.7	CH	nd
18	15.9	CH ₃	0.74 s
19	19.0	CH ₃	0.95 s
20	196.3	С	
21	31.2	CH ₃	1.98 s
22	170.0	С	
23	33.9	CH_2	2.25, nd
24	24.7	CH ₂	1.48, nd
25	31.6	CH	1.80 m
26	75.6	CH_2	3.96, 4.08 m
27	16.7	CH_3	0.94 d (6.43)

a) Measured at 600 MHz for ¹H and 150 MHz for ¹³C with reference to pyridine- d_5 . b) Multiplicities were assigned from DEPT spectra. c) nd: not determined. d) Overlapping ¹H-NMR signals are reported without designated multiplicities.

Table 2. ¹H- and ¹³C-NMR Data of the Sugar Moieties of **1** (in Pyridine- d_z),^{*a,b*)} δ in ppm (*J* in Hz)

	$\delta_{ m c}$	$\delta_{ ext{ H}}$
Sugars at C-3		
Gle I		
1	99.7	4.84 d (7.4)
2	78.0	4.16
3	77.1	4.04
4	77.9	4.06
5	77.8	3.86
6	60.8	3.98, 4.12
T-Rha I		
1	101.6	6.10 br s
2	71.6	4.68
3	71.6	4.56
4	73.5	4.20
5	69.2	4.78
6	18.3	1.65 d (6.2)
Rha II		
1	101.7	5.58 s
2	72.0	4.35
3	71.0	4.02
4	79.8	4.26
5	68.1	4.64
6	18.0	1.46 d (6.4)
T-Rha III		· /
1	102.6	6.03 s
2	72.0	4.38
3	71.9	4.44
4	73.5	4.26
5	69.9	4.19
6	18.3	1.70 d (6.0)
Sugars at C-26		
Glc II		
1	104.1	4.75 d (7.8)
2	74.4	3.90
3	77.6	4.18
4	71.0	4.00
5	77.9	3.90
6	62.1	4.18, 4.40

 Table 3. Antifungal Activity of 1—4 and Ketoconazole against Candida

 Species Given as MIC $(\mu g/ml)^{a}$

Compounds	Candida albicans	Candida glabrata	Candida tropicalis
1—3	>200	>200	>200
4	20.80	25	6.25
Ketoconazole ^{b)}	1.56	0.78	0.78

a) Compounds with MIC values $>200 \,\mu g/ml$ are considered not active. b) Positive control.



a) The assignments were based on the DEPT, HSQC, and HMBC experiments (150 MHz for ¹³C-NMR, 600 MHz for ¹H-NMR). *b*) Overlapping ¹H-NMR signals are reported without designated multiplicities.

the basis of the above results, compound 1 was deduced to be 26-*O*- β -D-glucopyranosyl-3 β ,26-dihydroxy-20,22-seco-25(*R*)-furost-5-en-20,22-dione-3-*O*- α -L-rhamnopyranosyl-(1 \rightarrow 4)- α -L-rhamnopyranosyl-(1 \rightarrow 4)-[α -L-rhamnopyranosyl-(1 \rightarrow 2)]- β -D-glucopyranoside (Fig. 1), a new natural compound.⁴)

Compounds 2—4 were identified by interpretation of their spectral data, mainly FAB-MS and 2D-NMR (COSY, TOCSY, NOESY, HSQC and HMBC), as well by comparison with literature data as methyl protodioscin (2),⁵⁾ asperoside (3),⁶⁾ and prosapogenin A of dioscin (4),⁷⁾ respectively.

The antifungal activity of saponins 1—4 (Table 3) was evaluated at concentrations of less than 200 μ g/ml against strains of *Candida albicans*, *C. glabrata* and *C. tropicalis*. Compound 1 presented MIC values above 200 μ g/ml, and was considered inactive against the yeasts tested. Compounds 2—3, having a furostan skeleton, were also devoid of activity against the tested fungi. Compound 4, having a spirostan skeleton, presented antifungal activity against *Candida* species with MIC values between 6.25 and 25 μ g/ml. Regarding the aglycone structure, we confirmed the presence of antifungal activity only with the spirostanol

Fig. 1. Chemical Structure of 1

derivative, whereas none was observed with the furostanol derivatives.¹⁾ This confirms that the E and F rings of diosgenin play a key role in the antifungal properties.⁸⁾

Experimental

General Experimental Methods IR, FAB-MS, 2D-NMR (COSY, TOCSY, NOESY, HSQC and HMBC), medium-pressure liquid chromatography (MPLC) instruments and GC analysis were as previously described.⁹) HR-ESI-MS was carried out on a Q-TOF 1-micromass spectrometer. Optical rotations were taken with a Perkin-Elmer 881 polarimeter. TLC and HPTLC were performed on silica gel plates 60 F_{254} (Merck), using the following solvent systems: (a) for saponins CHCl₃–MeOH–H₂O (13:7:2; lower phase), (b) for sapogenins CHCl₃–MeOH (9:1), and (c) for sugars CHCl₃–MeOH–H₂O (8:5:1).

Plant Material The rhizomes of *Dioscorea cayenensis* LAM.-HOLL were collected in October 2002 from Elounden (Yaounde Province, Cameroon), and identified by the Dr. Nole Tsabang (Institut de Recherches Médicales et d'Etudes des Plantes Médicinales, IMPM). A voucher specimen (No. 14259 HNC) is deposited at the National Herbarium of Yaoundé, Cameroon.

Extraction and Separation Dried powdered rhizomes (800 g) of *D. cayenensis* were refluxed with MeOH–H₂O (7:3, 61), and evaporated to dryness yielding 17.9 g of MeOH–H₂O extract. This was partitioned successively with hexane, CH₂Cl₂ and *n*-BuOH (each 3×200 ml) yielding after evaporation of the solvents the corresponding hexane (2 g), CH₂Cl₂ (1.3 g) and *n*-BuOH (7 g) fractions. 5 g of the *n*-BuOH residue was dissolved in MeOH and purified by precipitation with diethyl ether (3×300 ml), yielding a crude saponin mixture (3.45 g). This latter was submitted to the vacuum liquid chromatography on C₁₈ reversed-phase (12×3 cm) using H₂O (100 ml), MeOH–H₂O mixtures (5:5; 4:1, each 100 ml) and finally MeOH

(100 ml). The fraction eluted with MeOH–H₂O (4:1) was submitted to MPLC column chromatography (Si gel (15—40 μ m), CHCl₃–MeOH–H₂O (13:7:2, lower phase)), yielding 7 fractions, 1—7. Fraction 2 was concentrated to dryness to give the pure compound **1** (8 mg). Fractions 4 and 7 were rechromatographed under the same conditions to give the pure compounds **2** (10 mg) and **3** (7 mg), respectively. The fraction eluted with 100% MeOH was submitted to an additional MPLC in the same conditions to give 6 fractions, 1—6. Fraction 2 was rechromatographed by using MPLC in the same conditions to give the pure compound **4** (7 mg).

26-*O*-β-D-Glucopyranosyl-3β,26-dihydroxy-20,22-seco-25(*R*)-furost-5en-20,22-dione-3-*O*-α-L-rhamnopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→4)-[α-L-rhamnopyranosyl-(1→2)]-β-D-glucopyranoside (1): white amorphous powder, HR-ESI-MS (positive ion-mode) *m*/*z*: 1231.5697 [M+Na]⁺, (Calcd for C₅₇H₉₂O₂₇Na: 1231.5724). FAB-MS (negative ion mode) *m*/*z*: 1207 [M-H]⁻. [α]_D²⁰ +80° (*c*=0.025, MeOH). IR v_{max} (CHCl₃) cm⁻¹: 3371 (OH), 2929 (CH), 1736 (CO), 1680 and 1035. ¹H- and ¹³C-NMR: see Tables 1 and 2.

Acid Hydrolysis A solution of compound 1 (3 mg) in 2 N aqueous CF₃COOH (5 ml) was refluxed on a water bath for 3 h. After extraction with CH₂Cl₂ (3×5 ml), the aqueous layer was repeatedly evaporated to dryness with MeOH until neutral, and glucose was identified by TLC with a standard using CHCl₃–MeOH–H₂O (8:5:1). Furthermore, a silylated derivated of the sugar was prepared according to the procedure previously described.⁹) L-cysteine methyl ester hydrochloride (0.06 mol/l) and HMDS–TMCS (hexamethyldisilazane–trimethylchlorosilane, 3:1) were added to the aqueous residue. After centrifugation of the precipitate, the supernatant was concentrated and partitioned between *n*-hexane and H₂O, and the hexane layer was analyzed by GC. D-Glucose and L-rhamnose were detected.

Antifungal Activity Minimum inhibitory concentrations (MICs) were performed using the broth dilution test.¹⁰⁾ For these bioassays, three human

pathogenic yeasts were used: *Candida albicans* (IP 1180-79), *C. glabrata* and *C. tropicalis* (clinical isolates). The reference compound ketoconazole $(Sigma)^{11}$ was used as a positive control.

Acknowledgments The authors thank Dr. F. Libot, University of Paris V, France, for the measurement of HR-ESI-MS.

References

- Sautour M., Mitaine-Offer A. C., Miyamoto T., Dongmo A., Lacaille-Dubois M. A., *Planta Med.*, **70**, 90–92 (2004).
- Dong M., Feng X. Z., Wang B. X., Wu L. J., Ikejima T., *Tetrahedron*, 57, 501—506 (2001).
- Dong M., Feng X. Z., Wu L. J., Wang B. X., Ikejima T., *Planta Med.*, 67, 853—857 (2001).
- Buckingham J. B., "Dictionary of Natural Products on CD-ROM," Version 11:2, Chapman and Hall, CRC press, London, 2003.
- Hu K., Dong A., Yao X., Kobayashi H., Iwasaki S., *Planta Med.*, 63, 161–165 (1997).
- Mahato S. B., Ganguly A. N., Sahu N. P., *Phytochemistry*, 5, 959–978 (1982).
- Hu K., Dong A., Yao X., Kobayashi H., Iwasaki S., *Planta Med.*, 62, 573–575 (1996).
- 8) Takechi M., Tanaka Y., Phytochemistry, 8, 2557-2558 (1991).
- Haddad M., Miyamoto T., Laurens V., Lacaille-Dubois M. A., J. Nat. Prod., 66, 372–377 (2003).
- Quiroga E. N., Sampietro A. R., Vattuone M. A., J. Ethnopharmacol., 74, 89–96 (2001).
- Favel A., Steinmetz M. D., Regli P., Vidal-Ollivier E., Elias R., Balansard G., *Planta Med.*, **60**, 50–53 (1994).